RE:RE:Well market not happy !I agree, seems like after overblown response like there was to P4 in Phase I. Also maybe Covid did us a favour, better to fine tune screening and under dosing glitches after 12 patients being treated rather than 100. Just like we saw great improvement for P5 and P6 the next slew of results will tell the real tale.
2for1split wrote: It's not like we were priced for perfection.
This is just a blip, no reasoon to be punished for a 60% CR.
I dont think you will find any other company with a 35 million MC demonstrating 60% CR in a phase 2 trial.